Aamir Khan's production house unveiled 'Happy Patel: Khatarnak Jasoos', a spy comedy marking Vir Das's directorial debut. A ...

Vir Hirani, son of filmmaker Rajkumar Hirani, is set to make his OTT debut in Shakun Batra’s upcoming film. While discussions ...

Today is shaping up negative for Vir Biotechnology, Inc. (NASDAQ:VIR) shareholders, with the analysts delivering a substantial negative revision to next year's forecasts. Revenue estimates were cut ...

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination ...

Contrary to his name and general public perception, Vir Das (pronounced VEEr DAHs) is not completely devoid of fear. You would be forgiven for making the assumption, considering the sheer laundry list ...

The Central Government has released a gazette notification listing gallantry award citations for defence personnel from multiple operations, including Operation Sindoor. The citations highlight acts ...

Artists take on vengeance in a shutdown, the hounds of Pam Bondi, and more From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Investing.com -- Vir Biotechnology Inc (NASDAQ:VIR) stock rose 4.3% Thursday after the company announced it has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating VIR-5500 in ...

– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC – Clinical ...

SAN FRANCISCO, October 07, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present Week 48 endpoint results from the SOLSTICE Phase 2 clinical study ...

– Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented – Vir Biotechnology to ...

Vir Biotechnology, Inc. (NASDAQ:VIR), currently trading at $5.02, has seen its stock decline over 34% year-to-date, reflecting investor concerns despite its potential in treating serious infectious ...